Kan, M., Guo, G., Singh, B., Singh, V
This information helps clinicians determine whether symptoms might relate to medication side effects (such as dehydration from vomiting) or represent an independent medical issue requiring specific treatment
The identification and quantification of the most recurrent adverse effects (TABLE 2) associated with tirzepatide are central to understanding its clinical safety profile
In the coming years, several trends are likely to emerge: Rapid growth in the number of oral GLP-1 drugs Small-molecule GLP-1 therapies becoming a major R&D focus Manufacturing capacity becoming a key competitive factor Continued entry of emerging biotechnology companies into the sector At the same time, dual-target GLP-1 drugs , GLP-1/GIP co-agonists , and oral multi-target metabolic therapies are also advancing rapidly
He graduated from medical School at the Catholic University of Sacred Heart in Rome